J. Secrist

发表

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

L. Schwartz, H. Scher, P. Marks, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events.

R. Abraham, L. Karnitz, G. Koretzky, 1993, The Journal of biological chemistry.

SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

C. Kenific, Melissa Chenard, A. Kral, 2008, Bioorganic & medicinal chemistry letters.

The GTPase-activating protein of Ras suppresses platelet-derived growth factor beta receptor signaling by silencing phospholipase C-gamma 1

A. Kazlauskas, J. Secrist, M. Valius, 1995, Molecular and cellular biology.

Signal transduction through the T-cell antigen receptor.

R. Abraham, L. Karnitz, P. Leibson, 1992, Trends in biochemical sciences.

HDAC inhibitors for the treatment of cancer.

V. Richon, J. Secrist, Xianbo Zhou, 2003, Current opinion in investigational drugs.

C-gamma 1. receptor signaling by silencing phospholipase suppresses platelet-derived growth factor beta The GTPase-activating protein of Ras

A. Kazlauskas, J. Secrist, M. Valius, 2013 .

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Joshua Close, Sriram Tyagarajan, C. Kenific, 2008, Bioorganic & medicinal chemistry letters.

Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.

C. Kenific, Melissa Chenard, A. Kral, 2014, ACS medicinal chemistry letters.

Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).

J. Grimm, Melissa Chenard, A. Kral, 2009, Bioorganic & medicinal chemistry letters.

Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

Jessica E. Bolden, R. Dickins, S. Minucci, 2013, Molecular Cancer Therapeutics.

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).

Melissa Chenard, A. Kral, B. Haines, 2008, Bioorganic & medicinal chemistry letters.

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

E. Hennessy, S. Fawell, B. Davies, 2021, Communications biology.

T-cell antigen receptor ligation induces tyrosine phosphorylation of phospholipase C-gamma 1.

R. Abraham, L. Karnitz, J. Secrist, 1991, The Journal of biological chemistry.

Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine.

G. Powis, R. Abraham, J. Secrist, 1990, The Journal of biological chemistry.

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

Jessica E. Bolden, J. Bolden, R. Johnstone, 2008, Proceedings of the National Academy of Sciences.

Benzo[b]thiophene-based histone deacetylase inhibitors.

R. Mosley, Thomas A. Miller, J. Secrist, 2007, Bioorganic & medicinal chemistry letters.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

J. A. Hendricks, David M. Wilson, S. Kazmirski, 2018, Nature Communications.

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Tristan J. Lubinski, E. Hennessy, M. Garnett, 2020, Clinical Cancer Research.

The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.

A. Kral, A. Szewczak, A. Hitz, 2007, Bioorganic & medicinal chemistry letters.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

B. Aldridge, L. Drew, A. Tron, 2020, CPT: pharmacometrics & systems pharmacology.

Signal transduction through the T cell antigen receptor. Activation of phospholipase C through a G protein-independent coupling mechanism.

R. Abraham, J. A. Augustine, P. Leibson, 1991, Journal of immunology.

Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.

V. Richon, Thomas A. Miller, J. Secrist, 2007, Bioorganic & medicinal chemistry letters.

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

A. Letai, L. Drew, A. Christie, 2019, Blood.

Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.

R. Hendrickson, C. Paweletz, Fanyu Meng, 2008, Journal of proteome research.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008 .

Abstract 311: AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models

E. Hennessy, J. Secrist, E. Clark, 2018, Molecular and Cellular Biology / Genetics.

Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.

C. Cordon-Cardo, P. Marks, M. Drobnjak, 2004, Methods in enzymology.

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

E. Hennessy, S. Fawell, B. Davies, 2021, Communications Biology.

Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).

J. Grimm, A. Kral, A. Szewczak, 2008, Bioorganic & medicinal chemistry letters.

Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers

S. Kazmirski, J. Tyner, D. Hargreaves, 2017 .